全文获取类型
收费全文 | 58938篇 |
免费 | 3556篇 |
国内免费 | 1567篇 |
专业分类
耳鼻咽喉 | 497篇 |
儿科学 | 1098篇 |
妇产科学 | 751篇 |
基础医学 | 4957篇 |
口腔科学 | 1134篇 |
临床医学 | 5584篇 |
内科学 | 6524篇 |
皮肤病学 | 489篇 |
神经病学 | 3180篇 |
特种医学 | 1637篇 |
外国民族医学 | 6篇 |
外科学 | 6638篇 |
综合类 | 10791篇 |
现状与发展 | 1篇 |
一般理论 | 4篇 |
预防医学 | 5090篇 |
眼科学 | 982篇 |
药学 | 4825篇 |
112篇 | |
中国医学 | 7919篇 |
肿瘤学 | 1842篇 |
出版年
2024年 | 137篇 |
2023年 | 1022篇 |
2022年 | 1593篇 |
2021年 | 2451篇 |
2020年 | 2232篇 |
2019年 | 2356篇 |
2018年 | 2079篇 |
2017年 | 1885篇 |
2016年 | 1759篇 |
2015年 | 1547篇 |
2014年 | 3707篇 |
2013年 | 3318篇 |
2012年 | 3258篇 |
2011年 | 4087篇 |
2010年 | 3702篇 |
2009年 | 2789篇 |
2008年 | 2595篇 |
2007年 | 2801篇 |
2006年 | 2596篇 |
2005年 | 2171篇 |
2004年 | 1756篇 |
2003年 | 1629篇 |
2002年 | 1123篇 |
2001年 | 1014篇 |
2000年 | 828篇 |
1999年 | 794篇 |
1998年 | 616篇 |
1997年 | 589篇 |
1996年 | 476篇 |
1995年 | 520篇 |
1994年 | 490篇 |
1993年 | 379篇 |
1992年 | 376篇 |
1991年 | 328篇 |
1990年 | 275篇 |
1989年 | 280篇 |
1988年 | 273篇 |
1987年 | 228篇 |
1986年 | 221篇 |
1985年 | 446篇 |
1984年 | 436篇 |
1983年 | 339篇 |
1982年 | 379篇 |
1981年 | 374篇 |
1980年 | 361篇 |
1979年 | 316篇 |
1978年 | 279篇 |
1977年 | 257篇 |
1976年 | 187篇 |
1975年 | 110篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
43.
Katherine M. Duszynski Nicole L. Pratt John W. Lynch Jesia G. Berry Michael S. Gold 《Vaccine》2019,37(2):280-288
Objective
To determine whether differences in combination DTaP vaccine types at 2, 4 and 6?months of age were associated with mortality (all-cause or non-specific), within 30?days of vaccination.Design
Observational nationwide cohort study.Setting
Linked population data from the Australian Childhood Immunisation Register and National Death Index.Participants
Australian infants administered a combination trivalent, quadrivalent or hexavalent DTaP vaccine (DTaP types) between January 1999 and December 2010 at 2, 4 and 6?months as part of the primary vaccination series. The study population included 2.9, 2.6, & 2.3?million children in the 2, 4 and 6?month vaccine cohorts, respectively.Main outcome measures
Infants were evaluated for the primary outcome of all-cause mortality within 30?days. A secondary outcome was non-specific mortality (unknown cause of death) within 30?days of vaccination. Non-specific mortality was defined as underlying or other cause of death codes, R95 ‘Sudden infant death syndrome’, R96 ‘Other sudden death, cause unknown’, R98 ‘Unattended death’, R99 ‘Other ill-defined and unspecified cause of mortality’ or where no cause of death was recorded.Results
The rate of 30?day all-cause mortality was low and declined from 127.4 to 59.3 deaths per 100,000 person-years between 2 and 6?month cohorts. When compared with trivalent DTaP vaccines, no elevated risk in all-cause or non-specific mortality was seen with any quadrivalent or hexavalent DTaP vaccines, for any cohort.Conclusion
Use of routine DTaP combination vaccines with differing disease antigens administered during the first six months of life is not associated with infant mortality. 相似文献44.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献45.
46.
《Taiwanese journal of obstetrics & gynecology》2020,59(5):669-674
ObjectivesTo compare fetal anterior abdominal wall thickness (AAWT) between women with and without GDM during third trimester and to determine accuracy of AAWT to predict large for gestational age (LGA) infants.Materials and methodsA total of 250 pregnant women, including 125 women with GDM and 125 women without GDM, were enrolled. Tansabdominal ultrasonographic examinations were performed at 28–30, 32–34 and 36–38 weeks. In addition to standard fetal biometries, AAWT was measured. Patient characteristics and ultrasonographic measurements were compared between groups. Sensitivity and specificity of AAWT for identifying LGA were evaluated.ResultsWhile standard fetal biometries were comparable, mean fetal AAWT in GDM women were significantly higher than those without GDM at 28–30 weeks (2.8 ± 0.8 vs. 2.6 ± 0.6, p = 0.006) and 32–34 weeks (4.0 ± 0.9 vs. 3.5 ± 0.8, p = 0.042). LGA infants had significantly higher fetal AAWT at each time point only in GDM women. Using cut off values of AAWT of ≥2.0, 3.0, and 4.0 mm at 28–30, 32–34, and 36–38 weeks, sensitivity for LGA diagnosis in GDM women were 94.4%, 93.9%, and 89.3%, respectively. The use of abdominal circumference (AC) at >90th percentile showed lower sensitivity but higher specificity, regardless of GDM status. Combination of both measurements increased sensitivity to approximately 90% or higher in every time point, especially among GDM women.ConclusionSignificant increase in fetal AAWT was observed in GDM women at 28–30 and 32–34 weeks. Fetal AAWT significantly increased among LGA infants and had higher sensitivity than AC in identifying LGA during third trimester. In GDM women at 28–30 weeks, AAWT ≥2.0 mm and AC >90th percentile had 97.2% sensitivity for LGA diagnosis. 相似文献
47.
2019年12月始,新型冠状病毒肺炎(Corona Virus Disease 2019,COVID-19)以湖北武汉为中心向全国各地蔓延。目前数据显示,COVID-19合并糖尿病、高血压、肿瘤等基础病的患者病情较为严峻,病死率相对较高。该类患者的临床治疗策略有待进一步深入研究。在此次疫情防治过程中,中西医结合治疗手段于COVID-19的防治及患者基础疾病的兼顾治疗方面展现出了一定的特色及优势。本文结合中医“未病先防,既病防变,瘥后防复”思想,拟从COVID-19合并糖尿病、高血压、肿瘤三个方面,探讨COVID-19爆发形势下合并基础病患者的中医药防治策略。 相似文献
48.
王俊平 《中国继续医学教育》2020,(3):183-185
目的探讨对冠心病心绞痛患者给予健康教育联合心理护理干预后对其生活质量等方面产生的影响。方法选择我院2017年4月-2019年2月收治的100例冠心病心绞痛患者作为实验对象;抽签法分组后探究每组患者护理方式;对照组(50例):选择基础护理方式展开疾病护理;试验组(50例):选择基础护理+健康教育+心理护理方式展开疾病护理;对比各组患者表现出的护理工作满意度以及生活质量评定差异。结果试验组冠心病心绞痛患者护理工作总满意度(98.00%)高于对照组(82.00%)明显(P<0.05);试验组冠心病心绞痛患者睡眠情感、社会生活、精力以及躯体活动评分均高于对照组(P<0.05)。结论冠心病心绞痛患者在接受临床护理工作期间,对于护理工作满意度的提升,各项生活质量指标(睡眠情感、社会生活、精力以及躯体活动)评分结果的提升,均获得明显作用效果,最终对于冠心病心绞痛患者生活质量以及康复状态的显著提升,奠定基础。 相似文献
49.
50.